Impact of PAMAM delivery systems on signal transduction pathways in vivo: Modulation of ERK1/2 and p38 MAP kinase signaling in the normal and diabetic kidney

This publication has 74 references indexed in Scilit:

• Cationic Polyamidoamine Dendrimers as Modulators of EGFR Signaling In Vitro and In Vivo
  PLOS ONE, 2015
• Activation of ErbB2 and Downstream Signalling via Rho Kinases and ERK1/2 Contributes to Diabetes-Induced Vascular Dysfunction
  PLOS ONE, 2013
• On the nanotoxicity of PAMAM dendrimers: Superfect® stimulates the EGFR–ERK1/2 signal transduction pathway via an oxidative stress-dependent mechanism in HEK 293 cells
  International Journal of Pharmaceutics, 2013
• Activation of EGFR/ERBB2 via Pathways Involving ERK1/2, P38 MAPK, AKT and FOXO Enhances Recovery of Diabetic Hearts from Ischemia-Reperfusion Injury
  PLOS ONE, 2012
• Angiotensin‐(1‐7) inhibits epidermal growth factor receptor transactivation via a Mas receptor‐dependent pathway
  British Journal of Pharmacology, 2011
• Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy
  Nephrology, 2011
• Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: a focus on toxicogenomics
  Expert Opinion on Drug Metabolism & Toxicology, 2010
• Nonviral delivery of synthetic siRNAs in vivo
  Journal of Clinical Investigation, 2007
• Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificity
  Advanced Drug Delivery Reviews, 2007
• Non-viral cancer gene therapy: Beyond delivery
  Gene Therapy, 2005